

Fetzima (levomilnacipran)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Fetzima (levomilnacipran), FDA approved in 2009, is a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder. Major depressive disorder (MDD) is a mental health disorder that causes symptoms of sadness, hopelessness, and loss of interest in things. It can disrupt relationships and everyday activities, such as work, school, and activities that are usually pleasant. There are many medications from several classes that are available to treat major depressive disorder including selective serotonin-reuptake inhibitors (SSRIs), serotonin- and norepinephrine-reuptake inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and other antidepressants (e.g., bupropion, mirtazapine, trazodone).

NOTE: Fetzima (levomilnacipran) is not approved for the management of fibromyalgia, and the efficacy and safety of the drug for the management of this condition have not been established.

Definitions

"Major depressive disorder", also known as (MDD), is a psychiatric condition characterized by persistent low mood, low energy, or loss of interest in enjoyable activities causing substantial impairment in daily

life. MDD is thought to be caused by a combination of genetic, environmental and psychological factors. Risk factors include family history, major life changes, certain medications, chronic health problems, and substance use disorders.

“Selective serotonin reuptake inhibitors (SSRIs)” are a class of drugs that work by increasing the availability of serotonin to transmit signals between neurons.

“Serotonin-norepinephrine reuptake inhibitors (SNRIs)” are a class of drugs that work by increasing the availability of serotonin and norepinephrine to transmit signals between neurons.

“Tricyclic antidepressants” are a class of drugs used in depression. The name “tricyclic” is derived from the three rings in their molecular structure.

Medical Necessity Criteria for Initial Authorization

The Plan considers Fetzima (levomilnacipran) medically necessary when ALL the following criteria are met:

1. The member is 18 years of age or older; *AND*
2. The member has a diagnosis of major depressive disorder (MDD); *AND*
3. The member is unable to use or has tried and failed TWO (2) therapies, each from a different class for at least six (6) weeks each:
 - a. Noradrenergic and dopaminergic antidepressants (bupropion); *and/or*
 - b. Noradrenergic and specific serotonin antidepressants (e.g., mirtazapine); *and/or*
 - c. Selective serotonin reuptake inhibitors (e.g., citalopram, escitalopram, fluoxetine, paroxetine, sertraline); *and/or*
 - d. Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine, venlafaxine IR/ER); *and/or*
 - e. Tricyclic antidepressants (e.g., amitriptyline, nortriptyline); *AND*
4. Clinical chart documentation is provided for review to substantiate the above listed requirements.

If the above prior authorization criteria are met, Fetzima (levomilnacipran) will be approved for up to a lifetime.

Experimental or Investigational / Not Medically Necessary

Fetzima (levomilnacipran) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Tobacco Use Disorders (TUD). There are no high-quality studies to support the safety and efficacy of Fetzima (levomilnacipran) for the management of TUD.
- Fibromyalgia. There are no high-quality studies to support the safety and efficacy of Fetzima (levomilnacipran) for the management of fibromyalgia. The manufacturer's package insert explicitly states that Fetzima (levomilnacipran) is not approved for fibromyalgia and safety and efficacy has not been established for this indication.

References

1. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd edition, 2010. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed July 25, 2022.
2. Balt S and Puzantian T. Four Newer Antidepressants: Should You Use Them? The Carlat Psychiatry Report, April 2016. Volume 14, Issue 4.
3. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76-95. doi: 10.3109/15622975.2014.1001786.
4. Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3(2):69-86.
5. Durgam S, Chen C, Migliore R, Prakash C, Thase ME. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. Depress Anxiety. 2019 Mar;36(3):225-234. doi: 10.1002/da.22872. Epub 2019 Jan 23.
6. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006;67(Suppl 4):14-21.
7. Fetzima (levomilnacipran) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2023.
8. Fetzima (levomilnacipran) [prescribing information]. Madison, NJ: Allergan USA Inc; February 2022.
9. Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Van Rhoads, R. S. (2010). American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder. Am J Psychiatry, 167(Suppl 10), 9-118.
10. Gitlin M. When First-Line Depression Treatments Don't Cut It: Newer Antidepressants and Sometimes, Antipsychotics. The Carlat Psychiatry Report, July 2017. Volume 15, Issue 7&8.
11. He H, Wang W, Lyu J, et al. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. J Psychiatr Res. 2018 Jan;96:247-259. doi: 10.1016/j.jpsychires.2017.10.018. Epub 2017 Oct 21.
12. Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed June 26, 2022.
13. Kishi T, Ikuta T, Sakuma K, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17.
14. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Can J Psychiatry. 2024 Sep;69(9):641-687. doi: 10.1177/07067437241245384. Epub

2024 May 6. Erratum in: Can J Psychiatry. 2025 Aug;70(8):652. doi: 10.1177/07067437251349087.

15. National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health & Clinical Excellence (NICE). 2010.
16. National Institute for Health and Care Excellent (NICE): Depression in adults (QS8). Published 29 March 2011, updated 29 June 2023. Available at: <https://www.nice.org.uk/guidance/qs8>. Accessed 10 Oct 2025.
17. Nikolitch K, Phillips JL, Daniels S, Blier P. Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range. J Clin Psychiatry. 2025 Aug 25;86(3):25m15867. doi: 10.4088/JCP.25m15867.
18. Puzantian T and Carlat DJ. General Prescribing Tips: Treatment Algorithm for Depression. Medication Fact Book for Psychiatric Practice, 5th edition, 2020. Newburyport, MA; Carlat Publishing, p27-32.
19. Qaseem A, Owens DK, Etzeandia-Ikobaltzeta I, et al. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):239-252. doi: 10.7326/M22-2056. Epub 2023 Jan 24. Erratum in: Ann Intern Med. 2023 Aug;176(8):1143-1144. doi: 10.7326/L23-0246.
20. Radecki DT, Robieson WZ, Gopalkrishnan M, Greenberg E, Aziz M. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. J Child Adolesc Psychopharmacol. 2024 Jun;34(5):241-250. doi: 10.1089/cap.2023.0080. Epub 2024 May 3.
21. Sambunaris, A et al. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder. International Clinical Psychopharmacology. 2014; 29(4): p197-205. doi: 10.1097/YIC.0000000000000033.
22. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5:. Obstetrics & Gynecology 141(6):p 1262-1288, June 2023. | DOI: 10.1097/AOG.00000000000005202.
23. VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office.
24. Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. J Affect Disord. 2018 Mar 1;228:1-12. doi: 10.1016/j.jad.2017.11.056. Epub 2017 Nov 16.

Clinical Guideline Revision / History Information

Original Date: 11/05/2020

Reviewed/Revised: 10/14/2021, 12/01/2021, 9/15/2022, 9/21/2023, 12/19/2024, 12/01/2025